A study of body composition is only as good as the thing doing the composing. Here that thing is a bathroom scale that sends a small current through your legs and infers what is between them.
That is a real measurement and a useful one. It is not the measurement the phrase “body composition” usually implies, and the difference matters more than the percentages do. [1]
What the numbers say
Over months 10 to 14, the GLP-1 group showed a median weight reduction of 9.8% against matched non-users. The paper attributes 7.5% to fat mass and 2.3% to muscle mass.
Those two add to 9.8 exactly, which tells you both are expressed as shares of body weight rather than of each tissue. Work it through and muscle accounts for roughly a quarter of everything lost — close to the range the imaging studies keep landing in, which is at least a point in the method’s favor.
Systolic blood pressure fell 2.5 mm Hg, interval 1.5 to 2.9. Diastolic fell 1.5, interval 1.2 to 1.9. Those came from 148 exposed people rather than 396.
Who is in a study made of scale data
People who bought a connected scale, linked it to an app, weighed themselves regularly for years, and then answered a survey about their medications. Both groups.
That is a population already engaged with measuring itself. Matching happens inside it, so it controls for differences between the people who are there and tells you nothing about the people who are not — the same structural limit as a study whose sample defines its own conclusion, arriving by a different route.
The prediction that may be a floor
The strongest predictor of what the authors call weight-loss quality was the muscle-to-fat ratio somebody started with. People with less muscle relative to fat lost more fat and kept more muscle.
Which is worth sitting with. Somebody carrying little muscle has little muscle available to lose, so a measure of how much muscle came off will look favorable for them almost by construction. Whether that is a clinical insight or an artifact of the ratio is not something this design can separate, and what muscle loss does to strength is a different question again.
What it is good for
Scale data has one genuine advantage over a trial: it keeps going. Nobody schedules a DXA scan for a Tuesday in month thirteen, and daily home weights across years are a record no clinic produces.
So read this as a long, noisy, densely sampled look at a self-selected group, and not as a body-composition study. It agrees roughly with better instruments on the split, which is reassuring, and it says nothing about what comes back afterward.